Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -1.22% 40.50 495,575 14:32:43
Bid Price Offer Price High Price Low Price Open Price
39.00 42.00 41.00 40.50 41.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 127.34 -73.30 -15.03 270
Last Trade Time Trade Type Trade Size Trade Price Currency
15:31:49 O 235,000 40.00 GBX

Benchmark (BMK) Latest News

More Benchmark News
Benchmark Takeover Rumours

Benchmark (BMK) Discussions and Chat

Benchmark Forums and Chat

Date Time Title Posts
23/7/202011:53SALMON prices 30 year high and CAT VACCINES are Go-Go547
22/5/201821:09Benchmark Holdings Plc405

Add a New Thread

Benchmark (BMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-04 14:31:5040.00235,00094,000.00O
2020-08-04 14:28:2440.00235,33094,132.00O
2020-08-04 13:32:3640.0010,2894,115.60O
2020-08-04 12:17:4940.3012,4865,031.86O
2020-08-04 11:51:5341.509137.77O
View all Benchmark trades in real-time

Benchmark (BMK) Top Chat Posts

Benchmark Daily Update: Benchmark Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 41p.
Benchmark Holdings Plc has a 4 week average price of 37p and a 12 week average price of 29p.
The 1 year high share price is 54p while the 1 year low share price is currently 26.50p.
There are currently 667,643,631 shares in issue and the average daily traded volume is 25,441 shares. The market capitalisation of Benchmark Holdings Plc is £270,395,670.56.
murdo mcsponge: The Norwegians like to think they know a lot about Aquaculture. The fact that this outfit has picked up a 10%+ interest, which when added to the other Norwegian Company's holding of,I think circa 30%, makes an impressive Norwegian interestin BMk. IMHO it bodes well for future growth in BMKK and its share price.
edmonda: after FY results showed progress in all divisions and Group revs up 8%, a full research update just published by Equity Development with increase in fair value to nearly twice current share price. Note is freely accessible here:
bsharman3: the share price has done nothing much since February.... At least it hasn't tanked like some of my other stocks!
murdo mcsponge: It's strange that the share price is dropping at the same time as an organisation is building a substantial holding in the Company.
btfd497: Been holding these for almost a year now. I should have taken some profits when it rose to 80p but i got greedy... I still have faith in the company and am wait for their next trading update so the share price can rise again. I think this is a great long term share.
john09: There was a placing in December 2015 for the major acquisition and that placing price was 86p I can’t see any other placings so that 86p holds us in good stead in terms of any potential overhang in that we aren’t yet even at that level despite this great sustained rise . The 86p was at a 7% discount (not much) from the 93p share price at the time Sorry edit I just see also a placing at 65p in August 2016 placed at a premium at the time btw of over 11% to the share price
btfd497: This share is like a Jack in the box. No movement for weeks and then it suddenly jumps up. Hopefully it carries on going up throughout January and then there’s good news on January 24th to push the share price up higher. Fingers crossed the good news continues throughout 2018 and we get to £1.
john09: Today's news I think is the kind of news a billion pound biotech would put out. Can I see the share price being £2 one day? Yes
john09: You mean the martket cap vs profit? Yes I think that's why I liken it to a biotech. In 2013 it listed at 64p but the share price opened at 75p and was £1.45 within days. Like I said not necessarily one to trade but stick it away I think it'll move nicely
jaknife: Buy note out from Kepler Cheuvreux this am. Target price 68p. One thing that I noted is that the total market cap at £230m is now pretty much what they paid to acquire Inve back in Dec 2015! ---------------------------------------------- With FY trading in line and assuming a 65% YOY recovery in EBITDA in fiscal 2018E, the share price has overreacted. We therefore upgrade our rating to Buy. This remains a high-risk, high-return investment case: Benchmark combines a lack of focus and capital discipline, with a unique growth portfolio exposed to high value added, early life stages of fish. FY trading update: no further deterioration FY trading indicated for EBITDA of GBP8.7-9.3m for fiscal 2017, versus our GBP9.2m. This implies that H2 results did not deteriorate further after a disappointing H1. H2 trends were broadly in line with expectations, including ongoing strong performance in Breeding & Genetics. Animal Health continued to see operational losses in H2, due to lower sales in Salmosan and investments in new products, but we assume these to be less severe than in H1. Also, WC and capex were under control. Upgrade from Hold to Buy We upgrade the stock from Hold to Buy. The share price has more than halved since January. We believe that current valuation levels have more than factored in the operational setbacks in fiscal 2017, as the trading update indicates that downside to our estimates for 2017/18 is limited. Moreover: 1) we project EBITDA to increase by 65% YOY in 2018E, with consensus assuming an increase of 100% YOY; and 2) prospects for the key AAN division (55% of group sales) have improved, as the worst in global shrimp production seems to be over. This is largely driven by strong growth in Ecuador and India, while production in China and Thailand is still under pressure, due to diseases and adverse weather conditions. Still we perceive that global shrimp output might grow by low-to-mid single digits in 2018, whereas the recent contract renewal with the GSL-Coop provides stability. TP and key risks The share price has proven be very volatile since 2015, which we believe is a reflection of low earnings visibility and the unrestrained expansion into new products and territories. We lower our TP by 8% to 68p by applying a slightly higher WACC of 9%, with our long-term growth rate still at 5%. Do note that our TP does not include the NPV of the product pipeline, which we estimate at 65p per share. The key risks to our investment case relate to: 1) a further broadening of the portfolio into new products, services and territories, whereas we prefer to see proof of success of all the existing initiatives first, before entering into new adventures; and 2) higher-than expected investment and start-up costs for new product introductions.
Benchmark share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200805 02:19:47